A multicentre, retrospective, cohort study analysing rates of clinical failure in patients with CRE cUTI/AP treated with CRE-targeted BL-BLI vs. alternative regimens
Latest Information Update: 18 Dec 2020
At a glance
- Drugs Avibactam/ceftazidime (Primary) ; Meropenem/vaborbactam (Primary) ; Aminoglycosides; Carbapenems; Fluoroquinolones; Minocycline; Polymixins; Tigecycline
- Indications Pyelonephritis; Urinary tract infections
- Focus Therapeutic Use
- 18 Dec 2020 New trial record
- 25 Oct 2020 Primary endpoint has not been met according to results presented at the IDWeek 2020(clinical failure)
- 25 Oct 2020 Results presented at the IDWeek 2020